+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy (Surgery, Radiology, Chemotherapy, Immunotherapy), By Animal (Canine, Feline), By Cancer Type (Skin Cancer, Lymphoma, Sarcomas), And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • August 2024
  • Region: United States
  • Grand View Research
  • ID: 5351633

U.S. Veterinary Oncology Market Growth & Trends

The U.S. veterinary oncology market size is expected to reach USD 1.08 billion by 2030, registering a CAGR of 10.76% from 2024 to 2030. The increasing prevalence of cancer in pets, willingness to spend on them by pet owners, and use of canines as a model for clinical trials by researchers are the key contributing factor toward the market growth. In addition, a rise in the incidence of cancer in the feline population and rising pet ownership resulting in the increased focus on pet health is further expected to spur the growth. Moreover, companies are increasingly adopting strategies, such as M&As, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their market position.

For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors. In addition, Elanco purchased Aratana Therapeutics for its pet products pipeline. The company also had an agreement to create rabacfosadine (Tanovea), a drug from VetDC. In addition, in July 2021, Elanco proclaimed that the FDA granted full approval of Tanovea for the lymphoma treatment in dogs. Hence, the market is expected to witness intense competition over the forecast period. The growing prevalence of cancer in companion animals is expected to propel the need for effective treatment options.

In canines, appendicular osteosarcoma is an extremely aggressive illness and curative-intent treatment comprises surgical resection of the tumor followed by chemotherapy to diminish the risk of tumor cells spreading to other areas, particularly the lungs. The golden retriever breed has been reported to have a high cancer prevalence compared to others. Golden Retriever is one of the favorite breeds in the U.S. and increasing concerns regarding the wellbeing of pets are contributing to the market growth. Clinical trials are a critical aspect of veterinary oncology. The accelerated number of clinical research involving surgical procedures in pets is further fueling the market growth.

For instance, in May 2019, Oregon State University conducted a research study stating that the risk of cancer recurrence reduced to 60% in dogs whose tumors were completely resected. With the growing number of pet parents in the U.S., animal health awareness is rising among people. In the U.S., various pet health awareness events are conducted to spread awareness, such as National Pet Week. The risk of animals spreading COVID-19 to individuals is considered to be little. The FDA is alert that the COVID-19 pandemic may influence the ongoing studies being conducted to provision new animal drug development. Thereby, guidelines were issued in April 2020 to help diminish the potential impact of the pandemic on new animal drug development.

U.S. Veterinary Oncology Market Report Highlights

  • The radiology segment is expected to dominate the market. Factors, such as increasing government initiatives for the establishment of new veterinary radiation centers and advancements in radiation technology, are expected to boost the segment growth
  • The immunotherapy segment is estimated to register the fastest CAGR from 2023 to 2030 owing to the growing number of veterinary centers focused on carrying out clinical trials in immunotherapy areas
  • Chemotherapy is estimated to be the second-largest therapy segment by 2030. According to the Cancer Veterinary Center, the most common canine & feline tumors treated with chemotherapy are osteosarcomas, lymphomas, hemangiosarcoma, mast cell tumors, bladder tumors, mammary gland tumors, etc.
  • The canine segment accounted for the largest revenue share in 2023. The high incidence of cancer in canines and ongoing product innovations in this domain contributed to the segment growth

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Scope
1.1.2. Estimates And Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis
1.6.2. Global Market: CAGR Calculation
1.7. Research Scope and Assumptions
1.7.1. List of Secondary Sources
1.7.2. List of Primary Sources
1.7.3. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Veterinary Oncology Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Increasing Prevalence Of Cancer In Pets
3.2.1.2. Increasing R&D In Pet Cancer Therapy
3.2.1.3. Growing Focus On Animal Safety
3.2.1.4. Growing Uptake Of Pet Insurance
3.2.1.5. Technological Advancements In Pet Cancer Treatment
3.2.1.6. Increase In Pet Population
3.2.2. Market Restraints Analysis
3.2.2.1. High cost of treatment
3.2.2.2. Adverse effects associated with therapies
3.2.2.3. Limited Clinical Evidence
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenges Analysis
3.3. U.S. Veterinary Oncology Market Analysis Tools
3.3.1. Porter’s Analysis
3.3.1.1. Bargaining power of the suppliers
3.3.1.2. Bargaining power of the buyers
3.3.1.3. Threats of substitution
3.3.1.4. Threats from new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental Landscape
3.3.2.5. Legal landscape
3.4. COVID-19 Analysis
3.5. Estimated Pet Population, by key countries
Chapter 4. U.S. Veterinary Oncology Market: Animal Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Veterinary Oncology Market Movement Analysis
4.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
4.4. Canine
4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
4.5. Feline
4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
4.6. Equine
4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Veterinary Oncology Market: Therapy Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Veterinary Oncology Market Movement Analysis
5.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
5.4. Radiotherapy
5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.2. Stereotactic Radiation Therapy
5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.2.2. LINAC
5.4.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.2.3. Other Type
5.4.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.4.3. Conventional Radiation Therapy
5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.5. Surgery
5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.6. Chemotherapy
5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.7. Immunotherapy
5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.8. Other Therapies
5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Veterinary Oncology Market Movement Analysis
6.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Cancer Type, 2018 to 2030 (USD Million)
6.4. Skin Cancer
6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
6.5. Lymphomas
6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
6.6. Sarcomas
6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Company Market Position Analysis/ Heat Map Analysis
7.3. Estimated Company Market Share Analysis, 2023
7.4. Strategy Mapping
7.4.1. Mergers & Acquisitions
7.4.2. Partnerships & Collaborations
7.4.3. Others
7.5. Company Profiles
7.5.1. Elanco
7.5.1.1. Participant’s Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Boehringer Ingelheim International GmbH.
7.5.2.1. Participant’s Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Zoetis
7.5.3.1. Participant’s Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. PetCure Oncology
7.5.4.1. Participant’s Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Accuray Incorporated
7.5.5.1. Participant’s Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Varian Medical Systems, Inc.
7.5.6.1. Participant’s Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Elekta AB.
7.5.7.1. Participant’s Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Karyopharm Therapeutics, Inc.
7.5.8.1. Participant’s Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Virbac.
7.5.9.1. Participant’s Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Merck & Co., Inc.
7.5.10.1. Participant’s Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Dechra Pharmaceuticals PLC
7.5.11.1. Participant’s Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives
7.5.12. NovaVive Inc.
7.5.12.1. Participant’s Overview
7.5.12.2. Financial Performance
7.5.12.3. Product Benchmarking
7.5.12.4. Strategic Initiatives
7.5.13. Ardent Animal Health, LLC (A BreakthrU Company).
7.5.13.1. Participant’s Overview
7.5.13.2. Financial Performance
7.5.13.3. Product Benchmarking
7.5.13.4. Strategic Initiatives
Chapter 8. Key Takeaways
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
Table 4 U.S. Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
Table 5 U.S. Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
Table 6 Company Overview
Table 7 Service Benchmarking
Table 8 Financial Performance
Table 9 Strategic Initiatives
List of Figures
Fig. 1 U.S. Veterinary Oncology Market Segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Data Analysis Models
Fig. 6 Market Formulation And Validation
Fig. 7 Data Validating & Publishing
Fig. 8 General methodology for a commodity flow analysis of U.S. Veterinary Oncology Market
Fig. 9 Commodity flow analysis
Fig. 10 Parent market analysis
Fig. 11 Market Snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Parent market value, 2023 (USD Billion)
Fig. 16 Ancillary market outlook, 2023
Fig. 17 U.S. Veterinary Oncology Market Dynamics
Fig. 18 Estimated animal population, 2018-2023 by key species and key countries
Fig. 19 U.S. Veterinary Oncology Market: PORTER’s analysis
Fig. 20 U.S. Veterinary Oncology Market: PESTEL analysis
Fig. 21 U.S. Veterinary Oncology Market by Animal: Key Takeaways
Fig. 22 U.S. Veterinary Oncology Market by Animal, 2023 & 2030
Fig. 23 Canine market, 2018 - 2030 (USD Million)
Fig. 24 Feline market, 2018 - 2030 (USD Million)
Fig. 25 Equine market, 2018 - 2030 (USD Million)
Fig. 26 Horses market, 2018 - 2030 (USD Million)
Fig. 27 U.S. Veterinary Oncology Market by Therapy: Key Takeaways
Fig. 28 U.S. Veterinary Oncology Market by Therapy, Market Share, 2023 & 2030
Fig. 29 Radiotherapy market, 2018 - 2030 (USD Million)
Fig. 30 Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
Fig. 31 LINAC market, 2018 - 2030 (USD Million)
Fig. 32 Other Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
Fig. 33 Conventional Radiation Therapy market, 2018 - 2030 (USD Million)
Fig. 34 Surgery market, 2018 - 2030 (USD Million)
Fig. 35 Chemotherapy market, 2018 - 2030 (USD Million)
Fig. 36 Immunotherapy market, 2018 - 2030 (USD Million)
Fig. 37 Other therapies market, 2018 - 2030 (USD Million)
Fig. 38 U.S. Veterinary Oncology Market by Cancer Type: Key Takeaways
Fig. 39 U.S. Veterinary Oncology Market by Cancer Type, Market Share, 2023 & 2030
Fig. 40 Skin Cancers market, 2018 - 2030 (USD Million)
Fig. 41 Lymphomas market, 2018 - 2030 (USD Million)
Fig. 42 Sarcomas market, 2018 - 2030 (USD Million)
Fig. 43 Other market, 2018 - 2030 (USD Million)
Fig. 44 Market Participant Categorization
Fig. 45 Heat map analysis
Fig. 46 Strategic Framework

Companies Mentioned

  • Elanco
  • Boehringer Ingelheim International GmbH
  • Zoetis
  • Elekta AB
  • PetCure Oncology
  • Accuray Incorporated
  • Varian Medical Systems, Inc. (parent company: Siemens Healthineers)
  • Virbac
  • Merck & Co., Inc.
  • Dechra Pharmaceuticals PLC
  • NovaVive Inc.
  • Ardent Animal Health, LLC (A BreakthrU Company)

Methodology

Loading
LOADING...

Table Information